Trials / Completed
CompletedNCT01021293
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine
Immunogenicity and Safety of GSK Biologicals' IPV (Poliorix™) in Infants
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,101 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 60 Days – 90 Days
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the immunogenicity and safety of Poliorix™ when administered to healthy Chinese infants at 2, 3 and 4 months of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Poliorix™ | 3 doses, intramuscular administration |
| BIOLOGICAL | Oral Poliovirus vaccine | 3 doses, oral administration |
Timeline
- Start date
- 2009-11-28
- Primary completion
- 2010-07-05
- Completion
- 2010-07-05
- First posted
- 2009-11-26
- Last updated
- 2020-01-21
- Results posted
- 2017-04-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01021293. Inclusion in this directory is not an endorsement.